Compare NetEase Inc (NTES) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Novo Nordisk A/S — how do they compare? NetEase Inc trades at $116.51 (market cap $74.79B), while Novo Nordisk A/S trades at $45.08 (market cap $198.57B). The key difference: Novo Nordisk A/S is far larger — about 2.7× NetEase Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| NTES | NVO | |
|---|---|---|
Market Cap | $74.79B | $198.57B |
Sector | Media | Health |
52-Week High | $159.34 | $63.98 |
52-Week Low | $109.26 | $35.29 |
Enterprise Value | $50.53B | $213.37B |
Dividend Yield | 2.53% | 4.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $119.45, up 0.13% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $1.77, missing expectations of $2.32, though revenue grew 8% year-over-year to $4.4 billion. Strong fundamentals include a 27.88% net income margin and $137.58 billion in cash, supporting dividend growth and AI investments.
Outlook is mixed: analyst consensus is strongly bullish (82% buy ratings), citing undervaluation and international expansion potential, but near-term risks include earnings volatility and competitive pressures in gaming. The stock offers value at a P/E of 15.93, yet technical weakness suggests cautious entry points near support at $117.
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
